Clinical trial · Interventional
Treatment of HPV Infection in Perimenopausal and Postmenopausal Women
Therapeutic Effect of Topical Estrogen and Human Interferon Alpha 2b Vaginal Effervescent Capsules in Perimenopausal and Postmenopausal Women With High-risk HPV Infection
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A randomized controlled study was conducted to determine the effects of vaginal estrogen and human interferon alpha 2b vaginal effervescent capsules on vaginal microecology in perimenopausal and postmenopausal women. To determine whether there is a synergistic effect between the two in the treatment of HPV infection in perimenopausal and postmenopausal women. To observe the effects of two drugs alone and combined on the vaginal immune environment of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HPV Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Human interferon alpha 2b vaginal Effervescent capsules | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Interferon group
- description
- Vaginal placement of human interferon alpha 2b vaginal effervescent capsules, one pill a day daily, 10 days, for a course of treatment, a total of 3 courses
- interventionNames
- Drug: Human interferon alpha 2b vaginal Effervescent capsules
- type
- EXPERIMENTAL
- label
- Promestriene group
- description
- promestriene cream vaginal medication, once a day, 1g each time, 10 days, for a course of treatment, a total of 3 courses of treatment
- interventionNames
- Drug: Human interferon alpha 2b vaginal Effervescent capsules
- type
- EXPERIMENTAL
- label
- Interferon + promestriene combination group
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 45 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria:
* The age of 45-65 years (inclusive);
* HPV test indicates positive cervical and vaginal high-risk HPV;
* Cervical HSIL was excluded according to the 2015 US Transitional Clinical Guidelines for Cervical Cancer Screening.
* Patients with high-grade cervical intraepithelial lesions, who have undergone cervical conotomy or have undergone total or subtotal hysterectomy in the past, and HPV tests indicate high-risk cervical and vaginal HPV infection;
* If the combination of clear vaginal inflammation, symptomatic treatment is needed, then the group test;
* If the patients were complicated with abnormal uterine bleeding or postmenstrual bleeding, the reproductive system tumor should be excluded and cured, and then the patients were re-enrolled.
⑦ Volunteer to participate in clinical studies and sign informed consent.
Exclusion Criteria:
* Allergic to human interferon alpha 2b vaginal effervescent capsules or prolestrene cream;
* Pregnant or lactating patients;
* Patients with abnormal vaginal bleeding without clear cause;
④Patients with cervical high-grade intraepithelial lesions, gynecological malignancies, serious heart, brain, kidney, immune, blood and other systems and psychiatric neuropsychological diseases;
⑤Patients with consciousness disorder and communication disorder can not cooperate with the experiment;
⑥ Patients considered unsuitable or refused to participate in this clinical trial.References
Publications (0)
Data not yet available